farmasino elagolix sodium

Elagolix Sodium (832720-36-2) Product Overview Elagolix sodium (ABT-620) is a small molecule, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist designed to provide effective treatment for endometriosis symptoms. Suppresses estradiol (E2) concentrations in a dose-dependent manner First orally available GnRH antagonist on the market Offers advantages over injectable peptide-based treatments Serves an estimated patient population of over 170 million women

Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)- (830346-47-9) Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)- is a key intermediate in the synthesis of Elagolix Sodium, serving as a crucial building block in pharmaceutical manufacturing processes. Product Specifications Product Name Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)- CAS No. 830346-47-9 Assay 98% End Use Elagolix Sodium Molecular Formula C13H10F4N2O2

2-fluoro-3-methoxyphenylboronic acid (352303-67-4) 2-fluoro-3-methoxyphenylboronic acid is a key intermediate in the synthesis of Elagolix Sodium. Product Name: 2-fluoro-3-methoxyphenylboronic acid CAS No.: 352303-67-4 Assay: 98% End Use: Elagolix Sodium Molecular Formula: CHBFO Molecular Weight: 169.95 Shelf Life: 2 Years Package: 25kg/drum